Medivir
2,75 SEK -0,72%2 investorer følger denne virksomhed
Medivir is a pharmaceutical company. The company develops drugs and treatments with a focus on cancers and other serious diseases. The company invests in indication areas where available treatment methods are limited or completely lacking research. Collaborations with other partners are part of the business model, and drug development, as well as commercialization, are conducted either in-house or in partnership with other pharmaceutical companies. The head office is located in Huddinge.
Omsætning
7,6 mio.
EBIT %
-1.202,63 %
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
NASDAQ Stockholm
MVIR
Daglig lav / høj pris
2,68 / 2,76
SEK
Markedsværdi
315,2 mio. SEK
Aktieomsætning
163,73 t SEK
Volumen
60 t
Seneste videoer
Finanskalender
Delårsrapport
06.11.2024
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
Linc AB | 11,2 % | 11,4 % |
Nordea Funds AB | 8,7 % | 8,9 % |
Avanza Pension | 7,2 % | 7,4 % |
Hallberg Management AB | 6,6 % | 6,7 % |
HealthInvest Partners AB | 3,7 % | 3,8 % |
Nordnet Pensionsförsäkring AB | 2,8 % | 2,9 % |
NGL Förvaltning AB | 2,4 % | 2,4 % |
Johan Claesson | 2,2 % | 2,3 % |
CA Fastigheter AB | 2,1 % | 2,1 % |
Privatperson | 2,1 % | 2,2 % |
ViserAlle indholdstyper
Medivir, Audiocast with teleconference, Q3'24
Medivir to present at the Pareto Securities Healthcare Conference
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools